MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-09-2026
Anixa Biosciences Net Income 2011-2026 | ANIX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Anixa Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.9 M | -12.6 M | -9.81 M | -13.6 M | -13 M | -10.1 M | -11.6 M | -14 M | -5.01 M | -5.02 M | -1.38 M | -9.61 M | -10.1 M | -4.25 M | -7.38 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.38 M | -14 M | -9.22 M |
Quarterly Net Income Anixa Biosciences
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.56 M | - | -2.26 M | -2.79 M | -3.18 M | - | -3.28 M | -3.14 M | -3.26 M | - | -2.51 M | -2.29 M | -2.32 M | -10.1 M | -2.75 M | -3.54 M | -2.21 M | -8.94 M | -4.33 M | -2.4 M | -2.59 M | -7.79 M | -2.56 M | -2.64 M | -4.97 M | -9.56 M | -2.14 M | -2.57 M | -1.84 M | -8.85 M | -5.48 M | -1.38 M | -3.6 M | -3.22 M | -1.79 M | 160 K | -1.59 M | -3.97 M | -1.1 M | -1.27 M | 3.75 M | -86.6 K | -1.6 M | -2.24 M | -3.61 M | -6.45 M | 411 K | -3.25 M | -2.09 M | -7.15 M | -2.58 M | -2.48 M | -886 K | -1.86 M | -629 K | -877 K | -1.53 M | -2.79 M | -1.77 M | -1.29 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.75 M | -10.1 M | -2.98 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Castle Biosciences
CSTL
|
-24.2 M | $ 20.54 | 2.55 % | $ 595 M |  USA |
 |
Fulgent Genetics
FLGT
|
-42.7 M | $ 17.38 | 5.91 % | $ 525 M | USA |
 |
Guardant Health
GH
|
-416 M | $ 118.01 | 2.64 % | $ 14.8 B | USA |
 |
Agilent Technologies
A
|
1.21 B | $ 114.79 | 0.93 % | $ 34.9 B | USA |
 |
ICON Public Limited Company
ICLR
|
791 M | $ 116.57 | 1.29 % | $ 9.62 B |  Irlanda |
 |
Illumina
ILMN
|
-1.22 B | $ 144.83 | 2.05 % | $ 23 B | USA |
 |
Celcuity
CELC
|
-177 M | $ 142.53 | 1.56 % | $ 6.66 B | USA |
 |
Co-Diagnostics
CODX
|
-46.9 M | $ 3.71 | 55.23 % | $ 4.94 M | USA |
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-12.8 K | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
-21.4 M | $ 21.57 | 1.99 % | $ 1.15 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.14 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
234 M | $ 94.47 | -1.69 % | $ 6.38 B | USA |
 |
Interpace Biosciences
IDXG
|
24.6 M | $ 1.8 | - | $ 7.96 M | USA |
 |
Medpace Holdings
MEDP
|
451 M | $ 430.1 | 1.95 % | $ 12.4 B | USA |
 |
Mettler-Toledo International
MTD
|
869 M | $ 1 090.45 | 0.72 % | $ 22.5 B |  Schweiz |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
Personalis
PSNL
|
-81.3 M | $ 8.25 | 3.77 % | $ 736 M | USA |
 |
Charles River Laboratories International
CRL
|
-144 M | $ 158.86 | 1.77 % | $ 7.87 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
NeoGenomics
NEO
|
-108 M | $ 9.11 | 2.36 % | $ 1.17 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-208 M | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
11.6 M | $ 19.04 | -1.14 % | $ 426 M | USA |
 |
Natera
NTRA
|
-548 M | $ 203.69 | -0.6 % | $ 20 B | USA |
 |
Myriad Genetics
MYGN
|
-366 M | $ 3.91 | 2.62 % | $ 362 M | USA |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
897 M | $ 27.15 | 1.53 % | $ 25.7 B |  Niderland |
 |
Twist Bioscience Corporation
TWST
|
-77.7 M | $ 58.84 | 9.64 % | $ 3.52 B | USA |
 |
Senseonics Holdings
SENS
|
-69.1 M | $ 6.16 | 7.88 % | $ 257 M | USA |
 |
QIAGEN N.V.
QGEN
|
425 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
20.9 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
-4.97 M | $ 2.44 | 3.83 % | $ 5.6 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
876 M | $ 255.75 | -0.65 % | $ 21.3 B | USA |
 |
Waters Corporation
WAT
|
643 M | $ 340.99 | -0.1 % | $ 20.3 B | USA |
 |
Thermo Fisher Scientific
TMO
|
6.7 B | $ 449.37 | -0.54 % | $ 169 B | USA |
 |
Trinity Biotech plc
TRIB
|
-31.2 M | $ 0.63 | 3.42 % | $ 226 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Exagen
XGN
|
-20 M | $ 4.27 | 11.49 % | $ 92.1 M | USA |
 |
Neogen Corporation
NEOG
|
-1.09 B | $ 8.86 | 0.34 % | $ 1.92 B | USA |